Theralink Technologies IncOTC Pink - Current Information:THER
- LAST PRICE0.0008
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0008/ 23,200
- Ask / Lots0.0010/ 2,172
- Open / Previous Close0.0000 / 0.0008
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | THER |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Theralink Technologies Inc | 4.9M | -0.3x | --- |
Lipella Pharmaceuticals Inc | 4.9M | -0.9x | --- |
Azitra Inc | 5.6M | -0.1x | --- |
Aditxt Inc | 3.7M | 0.0x | --- |
Soligenix Inc | 5.8M | -0.4x | --- |
TFF Pharmaceuticals Inc | 6.5M | -0.2x | --- |
Company Information
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
Contact Information
- Headquarters
- 8000 INNOVATION PARK, DR, BATON ROUGEBATON ROUGE, LA, United States 70820
- Phone
- 225-578-7555
- Fax
- ---
Executives
- Chairman of the Board
- Jeffrey Busch
- President, Chief Executive Officer, Chief Operating Officer
- Faith Zaslavsky
- Chief Financial Officer, Director
- Andrew Kucharchuk
- Chief Medical Officer, Director
- Michael Ruxin
- Independent Director
- Yvonne Fors
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.9M |
|---|---|
Revenue (TTM) | $635.5K |
Shares Outstanding | 6.2B |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.00 |
Book Value | $-0.01 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 7.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,251.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
